Jacob George

Jacob George's AcademicInfluence.com Rankings

Jacob George

Law

#1878

World Rank

#2344

Historical Rank

Common Law

#52

World Rank

#59

Historical Rank

law Degrees

Download Badge

Jacob George's Degrees

PhD Medical Research Monash University

Why Is Jacob George Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jacob George's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention (2018) (2834)
Telaprevir for previously untreated chronic hepatitis C virus infection. (2011) (2539)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) (2381)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (2009) (1941)
MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. (2020) (1293)
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome (2002) (1131)
A new definition for metabolic associated fatty liver disease: an international expert consensus statement. (2020) (1099)
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2019) (915)
Beyond insulin resistance in NASH: TNF‐α or adiponectin? (2004) (762)
Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression (2003) (664)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss (2009) (591)
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. (2006) (560)
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. (2005) (542)
Visceral fat: A key mediator of steatohepatitis in metabolic liver disease (2008) (539)
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis (2014) (518)
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. (2012) (502)
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates (2019) (452)
Animal models of nonalcoholic fatty liver disease (2011) (441)
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. (2018) (437)
Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C (2003) (433)
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (419)
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. (2013) (417)
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study (2011) (403)
Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. (2012) (394)
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. (2017) (388)
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response (2002) (378)
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? (2002) (364)
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection (2014) (348)
Transforming growth factor β and the liver (2001) (317)
Independent effects of physical activity in patients with nonalcoholic fatty liver disease (2009) (315)
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease (2020) (306)
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. (2003) (295)
Obesity Is a Risk Factor for Greater COVID-19 Severity (2020) (292)
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease (2020) (273)
NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. (2005) (271)
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. (2017) (264)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease (1995) (246)
Effect of aerobic exercise training dose on liver fat and visceral adiposity. (2015) (241)
HFE mutations, hepatic iron, and fibrosis: Ethnic‐specific association of NASH with C282Y but not with fibrotic severity (2002) (239)
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. (2015) (239)
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission (2019) (227)
Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. (2003) (223)
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. (2002) (210)
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (2004) (200)
Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection (2010) (195)
The changing epidemiology of liver diseases in the Asia–Pacific region (2018) (194)
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. (2008) (194)
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD (2020) (193)
Which patients with hepatitis C develop liver complications? (2000) (186)
IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study (2011) (184)
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B (2010) (179)
Genotype‐specific mechanisms for hepatic steatosis in chronic hepatitis C infection (2002) (175)
Fatty liver disease: NASH and related disorders (2004) (172)
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation (2020) (171)
Kupffer cells mediate leptin-induced liver fibrosis. (2009) (167)
Advancing the global public health agenda for NAFLD: a consensus statement (2021) (167)
Transforming growth factor beta and the liver. (2001) (166)
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (2006) (165)
Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders (2008) (165)
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease (2009) (160)
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores (2020) (159)
Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease (2011) (158)
Modelling the hepatitis C virus epidemic in Australia. (2007) (155)
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. (2012) (155)
Non‐alcoholic steatohepatitis in the Asia–Pacific region: Future shock? (2004) (154)
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology (2019) (153)
Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. (2010) (153)
The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. (2011) (152)
Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease (2010) (147)
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C (2014) (147)
ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis (2019) (145)
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease (2015) (144)
Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells (2017) (141)
Insulin resistance and liver injury in hepatitis C is not associated with virus‐specific changes in adipocytokines (2007) (141)
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. (2009) (141)
Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? (2011) (135)
Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. (1998) (131)
Genotype‐specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C (2008) (131)
Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. (1995) (130)
Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause? (2013) (128)
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis (2020) (120)
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. (2014) (118)
Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease (2020) (116)
Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. (1995) (115)
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors (2009) (113)
The role of diet and nutritional intervention for the management of patients with NAFLD. (2014) (104)
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016) (101)
Fibrosis progression in chronic hepatitis C virus infection (2004) (101)
Pathogenesis of NASH: animal models. (2007) (98)
Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis (96)
Thyrotoxicosis induced by alpha‐interferon therapy in chronic viral hepatitis (2002) (96)
Impact of common risk factors of fibrosis progression in chronic hepatitis C (2014) (96)
379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease (2014) (93)
Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease. (2019) (92)
Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients (2020) (90)
The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension. (2015) (88)
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease (2016) (87)
Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis (2003) (87)
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort (2011) (86)
Combined effects of different interleukin‐28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection (2012) (86)
A microRNA‐7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib‐resistant cells in human hepatocellular carcinoma (2017) (85)
Fatal outcome in a liver transplant recipient with COVID-19 (2020) (85)
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis (2017) (83)
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes (2016) (82)
Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. (2019) (78)
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. (2015) (77)
From NAFLD to MAFLD: a “redefining” moment for fatty liver disease (2020) (77)
Cytokines: From Clinical Significance to Quantification (2021) (76)
Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. (2008) (76)
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach (2021) (75)
Molecular mechanisms of insulin resistance in chronic hepatitis C. (2009) (75)
Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer (2014) (75)
Global multi-stakeholder endorsement of the MAFLD definition. (2022) (74)
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. (2021) (74)
Collagen biology and non‐invasive biomarkers of liver fibrosis (2020) (73)
High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study (2013) (72)
Current concepts on the role of nitric oxide in portal hypertension. (2013) (72)
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? (2021) (72)
Gender Differences in Healthy Ranges for Serum Alanine Aminotransferase Levels in Adolescence (2011) (70)
Metabolic‐associated fatty liver disease is associated with severity of COVID‐19 (2020) (70)
Aptamers: A promising chemical antibody for cancer therapy (2016) (69)
FibroGENE: A gene-based model for staging liver fibrosis. (2016) (68)
The membrane‐bound O‐acyltransferase domain‐containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B (2017) (68)
Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection (2013) (68)
Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. (2009) (67)
Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders (2012) (66)
Effects of Interferon Treatment Response on Liver Complications of Chronic Hepatitis C: 9-year Follow-Up Study (2004) (64)
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. (2015) (64)
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. (2019) (63)
Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer (2008) (63)
Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling (2014) (62)
The benefits of exercise for patients with non-alcoholic fatty liver disease (2015) (61)
Visceral adiposity in gastrointestinal and hepatic carcinogenesis. (2013) (61)
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice (2010) (58)
Host - hepatitis C viral interactions: The role of genetics. (2016) (58)
Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. (2019) (57)
Toward More Accurate Nomenclature for Fatty Liver Diseases (2019) (57)
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years (2015) (57)
Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate. (2020) (56)
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? (2021) (56)
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. (2008) (56)
Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. (2011) (55)
Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. (2012) (55)
Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers (2018) (54)
The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. (2017) (54)
High sensitivity C‐reactive protein values do not reliably predict the severity of histological changes in NAFLD (2004) (54)
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. (2009) (53)
The multifaceted and controversial immunometabolic actions of adiponectin (2014) (53)
Role of ethanol in the regulation of hepatic stellate cell function. (2006) (53)
MBOAT 7 rs 641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016) (53)
Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. (2019) (53)
Hepatitis C Virus Induces the Cannabinoid Receptor 1 (2010) (53)
Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients (2015) (52)
Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma (2016) (52)
Clinical significance of precore and core promoter mutations in genotype D hepatitis B‐related chronic liver disease (2008) (51)
Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C (2005) (50)
Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C (2011) (50)
The Geometric Framework for Nutrition as a tool in precision medicine (2017) (50)
The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. (2020) (49)
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. (2013) (48)
1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
Predictors of deferral of treatment for hepatitis C infection in Australian clinics (2011) (48)
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis (2012) (48)
Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells (2017) (47)
Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. (2013) (47)
Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. (2014) (46)
The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus (2019) (45)
Zinc is a potent and specific inhibitor of IFN-λ3 signalling (2017) (45)
Exercise and diet in the management of nonalcoholic fatty liver disease. (2016) (45)
LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study (2015) (45)
Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. (2014) (44)
Genetic Insights for Drug Development in NAFLD. (2019) (44)
Management of nonalcoholic steatohepatitis: an evidence-based approach. (2012) (44)
Genetic and epigenetic mechanisms of NASH (2016) (43)
Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. (2014) (43)
The Hepatitis C treatment experience: Patients’ perceptions of the facilitators of and barriers to uptake, adherence and completion (2015) (43)
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. (2014) (43)
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. (2021) (42)
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection (2018) (41)
Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes. (1997) (40)
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age‐dependent risk profiling study (2017) (40)
Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion* (2015) (40)
Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Non-carriers. (2020) (38)
Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C (2013) (38)
Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). (2016) (38)
A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD (2018) (37)
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines (2021) (37)
Macrophage Coordination of the Interferon Lambda Immune Response (2019) (36)
Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. (2014) (36)
Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. (2013) (35)
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy (2017) (35)
Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells (2015) (35)
Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial (2019) (35)
Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19 (2020) (34)
Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis (2017) (34)
Liver disease in adolescents: A cohort study of high‐risk individuals (2007) (34)
Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis. (2020) (33)
Effect of resveratrol on experimental non-alcoholic steatohepatitis. (2015) (33)
How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? (1998) (33)
KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. (2019) (33)
Overcoming treatment resistance in cancer: Current understanding and tactics. (2017) (33)
Fibrosis is not just fibrosis – basement membrane modelling and collagen metabolism differs between hepatitis B‐ and C‐induced injury (2016) (32)
Community-based hepatitis B screening: what works? (2014) (32)
1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY (2013) (32)
A systematic review and meta‐analysis of HCV clearance (2017) (32)
The antiviral role of zinc and metallothioneins in hepatitis C infection (2018) (31)
Macrophages in metabolic associated fatty liver disease (2020) (31)
Predicting the future burden of NAFLD and NASH. (2018) (31)
The nutritional geometry of liver disease including non-alcoholic fatty liver disease. (2018) (31)
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight (2022) (30)
An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. (2015) (30)
Influence of clinicopathological variables on CYP protein expression in human liver (1996) (30)
A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. (2021) (30)
Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. (2016) (30)
Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. (2013) (30)
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection (2012) (30)
Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population‐based cohort study, 1992–2007 (2011) (30)
Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression (2003) (29)
Hepatitis C treatment outcomes in Australian clinics (2012) (29)
Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. (2008) (29)
What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective (2020) (29)
Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? (2008) (29)
The role of IFN in the development of NAFLD and NASH. (2019) (28)
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C‐CORAL study (2018) (28)
Liver disease due to parenteral and enteral nutrition. (2004) (27)
Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19 (2020) (27)
10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. (2017) (26)
An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. (2020) (26)
Adiponectin confers protection from acute colitis and restricts a B cell immune response (2017) (25)
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
Non‐invasive estimation of liver fibrosis in non‐alcoholic fatty liver disease using the 13C‐caffeine breath test (2011) (25)
Nonalcoholic fatty liver disease burden: Australia, 2019–2030 (2020) (25)
Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications (2015) (25)
Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology (2018) (25)
Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. (2014) (25)
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. (2015) (25)
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region (2021) (25)
Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution (2015) (24)
IL 28 B , HLA-C , and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort : A Cross-Sectional Study (2011) (24)
COVID-19: The Immune Responses and Clinical Therapy Candidates (2020) (24)
Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study (2021) (24)
Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots (2014) (24)
Leptin and acetaldehyde synergistically promotes αSMA expression in hepatic stellate cells by an interleukin 6-dependent mechanism. (2011) (24)
Resistin mediates the hepatic stellate cell phenotype. (2013) (23)
Overview: An Introduction to NASH and Related Fatty Liver Disorders (2007) (23)
Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial (2017) (23)
Modulation of Notch signaling as a therapeutic approach for liver cancer. (2015) (23)
Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes. (1996) (23)
Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15) (2018) (23)
Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment (2018) (22)
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection (2018) (22)
HBV vaccination and HBV infection induces HBV-specific natural killer cell memory (2020) (22)
Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review (2013) (21)
Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease (2017) (21)
The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial (2020) (21)
A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice (2019) (21)
Role of human hepatic cytochromes P450 in drug metabolism and toxicity. (1991) (21)
Open‐label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C (2011) (21)
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non‐obese subjects with hepatitis C (2015) (21)
Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent (2014) (21)
Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C (2005) (20)
When a new definition overhauls perceptions of MAFLD related cirrhosis care. (2020) (20)
Yet more evidence that MAFLD is more than name change. (2021) (20)
Getting it right: the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers (2013) (20)
Non-contrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? (2021) (20)
Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response (2015) (20)
Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat (2016) (19)
COVID‐19 and liver transplantation: Lessons learned from three reported cases (2020) (19)
The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting (2017) (19)
Effectiveness of interferon alfa‐2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting (2003) (19)
Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019 (2021) (19)
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels (2019) (19)
High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. (2020) (19)
Biochemical markers of hepatic fibrogenesis: Single measurements are not reliable enough to replace liver biopsy (2000) (19)
A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. (2020) (19)
The role of AdipoR1 and AdipoR2 in liver fibrosis. (2018) (18)
Current approaches to the diagnosis and management of hepatocellular carcinoma (2005) (18)
Targeting IFN-λ: therapeutic implications (2016) (18)
Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals’ perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion (2017) (18)
Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study (2018) (18)
Compound K modulates fatty acid‐induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes (2013) (18)
Renal involvement in multicentric Castleman disease with glomeruloid hemangioma of skin and plasmacytoma. (2006) (18)
NAFLD Disease Burden - Australia, 2019-2030. (2020) (18)
Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. (2014) (18)
Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection (2020) (17)
IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis (2014) (17)
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B (2018) (17)
Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research. (2021) (17)
Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis (2021) (17)
A novel method to precisely quantify Hepatitis B Virus covalently closed circular (ccc)DNA formation and maintenance. (2020) (17)
Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012 (2018) (17)
Side effects are incompletely reported among systematic reviews in gastroenterology. (2015) (17)
Induced pluripotent stem cells (iPSCs) in the gastroenterology and hepatology: from basic research to clinical applications. (2015) (17)
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. (2016) (16)
Cohort Profile: Golestan Hepatitis B Cohort Study- A Prospective Long Term Study in Northern Iran (2014) (16)
Transient elastography in hepatitis C virus‐infected patients with beta‐thalassemia for assessment of fibrosis (2013) (16)
IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis (2019) (16)
A Sweet Connection? Fructose’s Role in Hepatocellular Carcinoma (2020) (16)
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin (2013) (16)
Interferon‐free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study (2016) (15)
Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates. (2021) (15)
Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver (2019) (15)
Practical Approach to the Diagnosis and Management of People With Fatty Liver Diseases (2007) (15)
M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) (2008) (15)
Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model (2019) (15)
Community-based prevention of hepatitis-B-related liver cancer: Australian insights. (2014) (15)
AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model (2019) (15)
Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray (2012) (15)
Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance (2002) (14)
Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation (2010) (14)
Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. (2020) (14)
No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression (2017) (14)
The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor α Agonist. (2015) (14)
NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by 1H‐MRS? (2017) (14)
The future liver of the Asia pacific: fatter and firmer from more fructose and fortune? (2013) (13)
E‐cigarettes damage the liver and alter nutrient metabolism in pregnant mice and their offspring (2020) (13)
Roles of adipokines in liver injury and fibrosis (2008) (13)
Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross‐sectional study of 9,447 people (2017) (13)
Are Non-alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease More Than Just Semantics? (2019) (13)
Fatty Acids Induce a Pro-Inflammatory Gene Expression Profile in Huh-7 Cells That Attenuates the Anti-HCV Action of Interferon. (2015) (13)
Elevated Liver Enzymes and Mortality in Older Individuals: A Prospective Cohort Study (2017) (13)
MAFLD: a holistic view to redefining fatty liver disease. (2021) (12)
64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS (2013) (12)
Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients (2020) (12)
Role of BMP-9 in human liver disease (2018) (12)
Instrumental support to facilitate hepatitis C treatment adherence: Working around shortfalls in shared-care (2014) (12)
NAFLD: The evolving landscape. (2018) (12)
Cost of treating chronic hepatitis B: comparison of current treatment guidelines. (2012) (12)
Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study (2015) (12)
ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver‐Related Cirrhosis (2020) (12)
Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers. (2020) (11)
Factors associated with HBV Virological Breakthrough (2016) (11)
NAFLD in Lean Asians (2020) (11)
Physical and chemical insults induce inflammation and gastrointestinal cancers. (2014) (11)
Non-alcoholic fatty liver disease (2009) (11)
Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? (2012) (11)
IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection (2016) (11)
Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry. (2021) (11)
Non‐alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats (2014) (11)
Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis (2017) (11)
Role of the constitutive androstane receptor (CAR) in human liver cancer. (2021) (11)
Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. (2013) (10)
Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice. (2020) (10)
Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014) (2017) (10)
Targeting cancer stem cells as a therapeutic approach in liver cancer. (2015) (10)
Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REV1TAL Study (2017) (10)
Interferon Lambda and Liver Fibrosis. (2019) (10)
Factors Associated with Non-Adherence to HBV Antiviral Therapy (2018) (10)
The effect of high-intensity interval training versus moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. (2021) (10)
Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis (2006) (10)
Exchange transfusion for severe intrahepatic cholestasis associated with sickle cell disease? (2002) (9)
CASE REPORT: Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features (2002) (9)
Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence (2021) (9)
Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B (2006) (9)
Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection (2013) (9)
Gliclazide-induced acute hepatitis with hypersensitivity features. (2002) (9)
Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific (2013) (9)
Interferon- l rs12979860 genotype and liver ﬁbrosis in viral and non-viral chronic liver disease (2015) (9)
Pharmacogenomics of hepatitis C infections: personalizing therapy (2012) (9)
Five‐year efficacy and safety of tenofovir‐based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy (2017) (9)
Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. (2014) (9)
Combined effects of different IL 28 B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection (2011) (9)
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention (2022) (9)
Distribution of interferon lambda‐3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies (2014) (9)
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. (2021) (9)
Randomized trial of albinterferon alfa‐2b every 4 weeks for chronic hepatitis C virus genotype 2/3 (2012) (8)
Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection (2016) (8)
Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia (2017) (8)
MAFLD: Now is the time to capitalize on the momentum. (2021) (8)
Hepatocyte- Specific Deletion of ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) Results in Altered Fibrotic Gene Expression in the Thioacetamide Model of Liver Injury (2015) (8)
Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future (2021) (8)
Animal Models of Hepatocellular Carcinoma (2012) (8)
Non-alcoholic fatty liver disease: more than just ectopic fat accumulation (2013) (8)
NAFLD/NASH is Not Just A ‘western’ on Problem: Some Perspectives on NAFLD/NASH from the East (2007) (8)
Angiopoietin-like proteins: another player in the metabolic field. (2006) (8)
Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease (2021) (8)
Transjugular liver biopsy effecting changes in clinical management. (2003) (8)
Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial (2017) (8)
Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (2016) (8)
Expansion of dysfunctional CD56‐CD16+ NK cells in chronic hepatitis B patients (2020) (8)
Liver-related effects of chronic hepatitis C antiviral treatment (2020) (8)
IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test (2013) (8)
Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus (2021) (8)
MAFLD and cardiovascular events: what does the evidence show? (2021) (7)
Current and novel therapies for the treatment of nonalcoholic steatohepatitis (2007) (7)
Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival (2021) (7)
Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study. (2021) (7)
Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis (2021) (7)
Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review (2020) (7)
Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease (2019) (7)
Prothrombotic factors and nonalcoholic fatty liver disease: An additional link to cardiovascular risk? (2014) (7)
Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users (2014) (7)
Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis (2022) (7)
Overview: Hepatocellular carcinoma - the future starts now (2009) (7)
TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. (2017) (7)
Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension (2021) (7)
Real World Evaluation of Viekira Pak (Ritonavir Boosted Paritaprevir, Ombitasvir and Dasabuvir +/− Ribavirin) in HCV Genotype 1 Targeting Advanced Liver Disease (The Revital Study) (2016) (7)
Predictors of liver-related complications in patients with chronic hepatitis C (2000) (7)
Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. (2021) (7)
Adipocyte‐hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease (2009) (6)
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (6)
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. (2013) (6)
Epidemiological Trends in NASH as a Cause for Liver Transplant (2016) (6)
Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort (2012) (6)
Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma (2020) (6)
Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with non-alcoholic fatty liver disease (2017) (6)
Plasma bile acids more closely align with insulin resistance, visceral and hepatic adiposity than total adiposity. (2020) (6)
The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region (2015) (5)
Metabolic and genetic contributions to NAFLD: really distinct and homogeneous? (2021) (5)
Clinical significance of IL28B gene variation in hepatitis C virus infection (2010) (5)
Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans (2016) (5)
P1007 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH FIBROSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C (2014) (5)
Hepatitis C virus eradication with interferon free, DAA-based therapy results in KLRG1+, hepatitis C virus-specific memory natural killer cells. (2020) (5)
Intra-familial Transmission of Chronic Hepatitis B Infection: A Large Population-Based Cohort Study in Northern Iran. (2018) (5)
Interleukin‐28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection (2014) (5)
Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? (2020) (5)
Worldwide lack of early referral of patients with alcoholic liver disease: results of the global alcoholic liver disease survey (GLADIS) (2017) (5)
Calsyntenin-1 mediates hepatitis C virus replication. (2016) (5)
Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. (2002) (5)
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection (2013) (5)
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types (2022) (5)
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis (2022) (5)
The importance and impact of recognizing metabolic dysfunction‐associated fatty liver disease in patients with chronic hepatitis C (2022) (5)
Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? (2011) (4)
Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis (2019) (4)
Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. (2013) (4)
Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice (2017) (4)
Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease (2021) (4)
All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy (2021) (4)
The many faces of hepatitis C: Liver disease and type 2 diabetes (2009) (4)
Hepatic Steatosis in Chronic Hepatitis C Infection (2002) (4)
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance (2020) (4)
Ltb4r1 inhibitor: A pivotal insulin sensitizer? (2015) (4)
1401 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES VARIANTS ASSOCIATED WITH LIVER FIBROSIS PROGRESSION IN HCV-INFECTED PATIENTS (2012) (3)
Reply: To PMID 24623375. (2015) (3)
Serum marker of inflammasome activity correlates with liver injury in nonalcoholic fatty liver disease and is influenced by genetic polymorphisms (2015) (3)
Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis (2020) (3)
Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus‐related carcinoma and prescribed anti‐viral therapy (2018) (3)
Pharmacotherapy of hepatocellular carcinoma (2003) (3)
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naive Subjects with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized Multinational Clinical Trial (2016) (3)
Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C (2013) (3)
The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population. (2021) (3)
Pre-treatment Antiviral Resistance in Australians with Chronic Hepatitis C: Prevalence of NS3 and NS5A Resistance Data in the State of New South Wales (2019) (3)
Tenofovir Rescue Therapy Achieves Long-Term Suppression of HBV Replication in Patients with Multi-Drug Resistant HBV: 4 Year Follow-Up of the TDF109 Cohort (2012) (3)
The effects of fructose and metabolic inhibition on hepatocellular carcinoma (2020) (3)
Updates in fatty liver disease: Pathophysiology, diagnosis and management. (2021) (3)
384 Chronic hepatitic C virus infection and insulin resistance: how do they interact, and what is the effect on hepatic fibrosis? (2003) (3)
The prevalence of gestational diabetes mellitus in women diagnosed with non-alcoholic fatty liver disease during pregnancy: A systematic review and meta-analysis. (2021) (3)
894 FEMALE SEX AND VARIATIONS IN IL28B ARE INDEPENDENTLY ASSOCIATED WITH SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION (2012) (3)
Bile acid composition modulates insulin resistance in non-diabetic patients with NAFLD (2018) (3)
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease (2021) (3)
Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells (2022) (3)
Dual proteotoxic stress accelerates liver injury via activation of p62‐Nrf2 (2021) (2)
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease (2016) (2)
The chicken or the egg: Adipocytes and hepatic insulin resistance (2010) (2)
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease (2020) (2)
The importance and impact of recognizing MAFLD in patients with chronic hepatitis C. (2021) (2)
Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection (2013) (2)
Editorial: triglycerides in chronic liver disease ‐ a marker of disease progression? (2015) (2)
High Prevalence of Abnormal Alanine and Aspartate Aminotransferases in a "Worried-Well" Population in the United Kingdom: Rationale for a Liver Screening Program? (2008) (2)
1328 IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION (2011) (2)
Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? (2014) (2)
A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes (2022) (2)
MAFLD, patient-centred care, and APASL (2022) (2)
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study (2017) (2)
Effects on serum albumin of response and relapse to lamivudine in patients with chronic hepatitis B (2000) (1)
Pregnancy complicated by refractory severe hypercholanaemia from sodium taurocholate co‐transporting polypeptide deficiency (2020) (1)
NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis (2013) (1)
461 SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION IS ASSOCIATED WITH FEMALE SEX, IL28B GENOTYPE AND HCV GENOTYPE 1 INFECTION (2013) (1)
MAFLD: a game changer redefining fatty liver disease for adults and children. (2021) (1)
Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease (2022) (1)
Selective reductions of individual cytochrome P450 isoforms in different types of human cirrhosis (1993) (1)
The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world (2020) (1)
Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals’ perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion (2018) (1)
Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy (2009) (1)
Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir. (2019) (1)
329 THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR) (2020) (1)
Ef fi cacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults : a pilot study (2015) (1)
Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study (2020) (1)
Erratum to: IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test (2015) (1)
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort (2022) (1)
Different contribution of metabolic and viral steatosis to liver damage (2005) (1)
Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir +/− ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis –Final results of the REV1TAL study (2017) (1)
Chapter 24. Recent Advances (2007) (1)
424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY (2011) (1)
A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses. (2014) (1)
Reply to: “The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease” (2012) (1)
Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection (2014) (1)
Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians (2020) (1)
Clinical Cases in Hepatitis: Towards improving liver disease management in Australia (2019) (1)
The macrophage activation marker, soluble CD163 is associated with hepatic inflammation and fibrosis in chronic viral hepatitis C and declines during effective direct-acting antiviral therapy (2017) (1)
COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out (2022) (1)
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease (2023) (1)
Lifestyle intervention in early liver disease: metabolic changes at 3 months (2006) (1)
Diabetes but Not Metabolic Syndrome Adversely Impact Survival or Liver Decompensation in Patients with Non-Alcoholic Fatty Liver Related Cirrhosis. (2018) (1)
Predicting liver-related events in non-alcoholic fatty liver disease: a novel predictive model. (2023) (0)
1076 INTERLEUKIN 6 REGULATES LIVER CANCER STEM CELLS (2013) (0)
Reply: (2009) (0)
952-P: Deranged Liver Enzyme Levels and Indices of Hepatic Steatosis and Fibrosis on the Development of Gestational Diabetes (2021) (0)
Liver disease progression and clinical outcomes in hepatic outcomes and survival fatty liver registry (HOTSURFR) study (2020) (0)
Hepatic macrophage activation is associated with adipose tissue insulin resistance in non-diabetic patients with Non-Alcoholic Fatty Liver Disease (2016) (0)
Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development (2022) (0)
Efficacy of the Omega-3 Index in predicting NAFLD in overweight and obese adults: A pilot study (2014) (0)
Reply to Letter to the Editor HEP-20-2462 and HEP-20-2655. (2020) (0)
1077 INTERLEUKIN 6, A POTENT REGULATOR OF Notch SIGNALING IN LIVER CANCER (2013) (0)
Evaluating patients who have abnormal liver tests (2002) (0)
Reply (2012) (0)
Circulating bile acids are associated with insulin resistance and visceral and liver fat in human subjects (2019) (0)
Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver (2019) (0)
HIGH SUCROSE MEDIATED ALTERATIONS IN GUT MICROBIOTA DISSOCIATE HEPATIC STEATOSIS FROM LIVER INFLAMMATION IN NAFL (2016) (0)
P1061 : The macrophage activation marker SCD163 and the apoptosis marker cytokeratin-18 are both predictors of disease severity in patients with non-alcoholic fatty liver disease (2015) (0)
Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales (2022) (0)
The Problem of Insulin Resistance and its Effect on Therapy (2011) (0)
Incidence and risk factors for cardiovascular events in patients with advanced fibrosis due to non-alcoholic steatohepatitis: data from the phase 3 STELLAR trials (2020) (0)
Efficacy of tenofovir disoproxil fumarate treatment in patients with a suboptimal response to adefovir dipivoxil (2010) (0)
Predictors for steatosis and fibrosis in chronic hepatitis C (2001) (0)
Effect of vitamin D analogue therapy in a patient with autosomal dominant hypocalcaemia type 2 (ADH2) due to GNA11 p.Arg60Leu mutation (2019) (0)
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (0)
Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets (2022) (0)
Mo1001 Prognostic Relevance of Serum Ferritin in Patients With Nonalcoholic Fatty Liver Disease (2013) (0)
State-of-the-Art Lecture: Non-alcoholic steatohepatitis: concepts on pathogenesis and therapy (2009) (0)
Treatment Targets and Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Summary of AALSD Trend Conference in NASH (2020) (0)
Micro-elimination of hepatitis C in mental health care settings (2020) (0)
Crosstalk between adipose tissue insulin resistance and liver macrophage activation in patients with Non-Alcoholic Fatty Liver Disease (2020) (0)
Association of variants of interleukin 10 and 12A with the progression of hepatitis B virus infection in Caucasians (2023) (0)
Omega-3 index and liver fat: An unexpected relationship (2014) (0)
Where the rubber meets the road in liver cancer prevention: Lessons from the B Positive project (2011) (0)
702 Amelioration of MCD-associated steatohepatitis by CYP2E1 inhibition: implications for the role of extra-mitochondrial source of pro-oxidants (2003) (0)
Mitosis of Hepatitis B virus-infected cells results in uninfected daughter cells (2022) (0)
Hepatitis C virus and metabolism. 2nd edition (2009) (0)
Serologically assessed fragments of type VI collagen are predictors of progression free survival and death in patients with hepatocellular carcinoma (2020) (0)
925 IL28B GENE VARIANTS AND METABOLIC PROFILE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (2012) (0)
Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison (2017) (0)
Reply: Iron and HFE mutations in nonalcoholic steatohepatitis: Innocent bystanders or accessories to the crime? (2003) (0)
Arabic and Assyrian immigrants’ knowledge of hepatitis and liver cancer in Sydney, Australia. Findings of a community consultation process. (2019) (0)
Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study (2022) (0)
Reply: (2007) (0)
TITLE PAGE Elevated liver enzymes and mortality in older individuals: a prospective cohort study (2016) (0)
Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up (2022) (0)
Editorial: Gene therapy for gastrointestinal and liver cancers: past experience, current status and future perspectives. (2015) (0)
Efficacy and safety of calcineurin inhibitors as salvage therapy in patients with autoimmune hepatitis (2018) (0)
Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? (2008) (0)
O211: With Interferon (2014) (0)
F-1 IL28B gene variants and metabolic profile in patients with genotype 1 chronic hepatitis C (2012) (0)
Table 1. Multiple Ordered Logistic Regression Analysis in Patients With HCV and HBV Infection (2015) (0)
Vitamin D deficiency: awaiting final proof? (2013) (0)
Reply: (2008) (0)
1071 HBV genotype & precore/precore promotor status in a Sydney population (2003) (0)
342 CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY (2021) (0)
Reply: (2008) (0)
831 DIFFERENTIAL GENE EXPRESSION OBSERVED IN HEPATITIS C GENOTYPES (2012) (0)
Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin (2016) (0)
Editorial: STAT‐4 polymorphism ‐ a tool to personalise clinical practice in chronic HBV infection. Authors’ reply (2018) (0)
Su1411 Seroclearance of Surface Ag in Genotype D Chronic Hepatitis B Infection: Results of a Large Population-Based Cohort Study (2015) (0)
Sa349 A GLOBAL SURVEY OF PHYSICIANS KNOWLEDGE ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) (2021) (0)
Su1407 Risk Factors Associated With Chronic Hepatitis B Infection in HBsAg Positive Individuals and Their First Degree Relatives: Results of a Large Population-Based Cohort Study (2015) (0)
12P The correlation between non-coding RNA and response rate to immune-checkpoint inhibitors (2020) (0)
Colour Plate Section (2004) (0)
Pseudohyponatremia in multiple myeloma. (2010) (0)
1069 A SIMPLE SCORING SYSTEM ACCURATELY EXCLUDES PORTAL FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (2012) (0)
P0760 : PNPLA3 rs738409 I748M is associated with steatohepatitis in non obese subjects with hepatitis C (2015) (0)
A maxillary mass in a HBV‐cirrhotic patient (2012) (0)
Transplantation: basic science (2013) (0)
P201 FATTY ACIDS INDUCE A PRO-INFLAMMATORY GENE EXPRESSION PROFILE IN HUH-7 CELLS AND ATTENUATE THE ANTI-HCV ACTION OF INTERFERON (2014) (0)
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus (2022) (0)
REPLY: (2021) (0)
326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY (2020) (0)
CLEARED Global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with Chronic Liver Disease (2022) (0)
Pre-treatment with cholic acid reduces MCD-diet induced liver injury (2008) (0)
Genes and NAFLD/NASH Progression (2020) (0)
Effect of combined fish oil plus coenzyme Q10 supplementation on Omega-3 Index and cardiovascular risk markers in overweight men (2016) (0)
Evolution of risk prediction models for post-operative mortality in patients with cirrhosis. (2023) (0)
Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY (2009) (0)
Reply: (2005) (0)
Mo1105 Side Effects Are Side Issues: Completeness of Reporting of Harms Among Systematic Reviews in Gastroenterology (2014) (0)
Does Alcohol Dependency Explain Differences in Rates of Decompensated Cirrhosis among People with a Hepatitis C Notification? An International Comparison (2016) (0)
Patients who leave without being seen. (1992) (0)
P56 INTERLEUKIN 6 IS A POWERFUL REGULATOR FOR ANGIOGENESIS IN LIVER CANCER (2014) (0)
AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model (2019) (0)
P.236 Hep573 study of complementary medicine for chronic hepatitis C (2006) (0)
Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making (2017) (0)
Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study (2022) (0)
Treating chronic hepatitis in Asian and Pacific Island populations: A comparison of program costs according to current treatment guidelines. (2012) (0)
Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis (2020) (0)
List of Abbreviations ADAMTS : A disintegrin and metalloproteinase with thrombospondin motifs ALT : Alanine Aminotransferase APRI : AST to Platelet Ratio Index AST : Aspartate Aminotransferase AUROC : Area under receiver operating curve (2018) (0)
The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international comparison study (2017) (0)
Community-Based Strategies to Improve Screening, Diagnosis and Linkage to Care for Patients with Chronic Hepatitis B (2019) (0)
P824 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (0)
P0223 : Role of ARL6IP5 in HCV-related hepatocellular carcinoma (2015) (0)
Predictors of non-adherence to HBV anti-viral therapy (2016) (0)
Hepatitis C and metabolism (2005) (0)
Concordance between missed days of hepatitis B virus anti-viral therapy and virological breakthrough (2016) (0)
adefovir dipivoxil in chronic hepatitis B following failure of both lamivudine and Tenofovir disoproxil fumarate rescue therapy (0)
Mo1458 - Response to Mycphenolate Mofetil in Patents with Autoimmune Hepatitis who Fail Standard Therapy is Predicted by Serum Gammaglobulin Levels but not Cirrhosis (2018) (0)
NON-CIRRHOTIC PORTAL FIBROSIS (2012) (0)
534 The Hep573 Study - A Randomized Double Blind Placebo Controlled Trial of Silymarin Alone or Combined With Antioxidants in Chronic Hepatitis C (2010) (0)
Reply (2015) (0)
Management of insulin resistance and type 2 diabetes associated with hepatitis C virus infection (2012) (0)
Impact of lifestyle modification on patients with chronic liver disease (2009) (0)
716 MOVING FROM PATIENT TO POPULATION-LEVEL HEPATITIS B MANAGEMENT IN AUSTRALIA (2010) (0)
Acute hepatitis A, B and C but not D is still incident in Mongolia: A time trend analysis (0)
Effect of progressive resistance training on liver fat in overweight adults: Moving beyond weight loss (2015) (0)
Zinc is a potent and speciﬁc inhibitor of IFN- l 3 signalling (2017) (0)
IL28B rs12979860 CC Genotype, Metabolic Profile and SVR in Patients with Genotype 1 Chronic Hepatitis C. (2012) (0)
P0229 : Jagged2-mediated notch signaling regulates cellular plasticity and promotes a cancer stem cell phenotype in HCC (2015) (0)
Title: PNPLA3 rs738409 I748M Variant and Histological Features of Nonalcoholic Steatohepatitis in Patients with Genotype 1 Chronic Hepatitis C SHORT TITLE: PNPLA3 AND NASH IN CHRONIC HEPATITIS C AUTHORS: (0)
The prevalence of metabolic dysfunction-associated fatty liver disease and its association on adverse pregnancy outcomes in women with gestational diabetes mellitus. (2022) (0)
University of Birmingham Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis (2014) (0)
Host genes and hepatitis C: recent advances (2010) (0)
Molecular Aspects of Hepatocellular Carcinoma (2018) (0)
Lean Metabolic-Associated Fatty Liver Disease (2023) (0)
ODP247 The Detection of Metabolic Dysfunction–Associated Fatty Liver Disease via Fibroscan® in Early–to–Mid Pregnancy is an Independent Risk Factor for the Development of Gestational Diabetes Mellitus (2022) (0)
PRO-C3 based sequential algorithm can screen high-risk NASH and severe fibrosis in asian NAFLD population (2022) (0)
Antenatal FibroScan® assessment for metabolic‐associated fatty liver in pregnant women at risk of gestational diabetes from a multiethnic population: a pilot study (2021) (0)
Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B (2022) (0)
Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH (2018) (0)
Elevated Hepatic Steatosis Index is Associated with the Development of Adverse Maternal, but Not Adverse Neonatal, Outcomes: A Retrospective Cohort Study. (2023) (0)
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study (2023) (0)
Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN). (2023) (0)
466 INTERLEUKIN-28B rs12979860 C ALLELE IS PROTECTIVE AGAINST ADVANCED FIBROSIS IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT (2013) (0)
A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD (2018) (0)
Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic NASH: an international study with 1,924 patients. (2023) (0)
Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. (2023) (0)
Lean non-alcoholic fatty liver disease patients from the global NASH registry (2022) (0)
SAT-419-Endotrophin, a fragment of collagen type VI formation (PRO-C6) is associated with progression free survival and mortality in patients with hepatocellular carcinoma (2019) (0)
IDDF2022-ABS-0120 Hepatocyte apoptosis fragment product cytokeratin-18 M30 and non-alcoholic steatohepatitis risk prediction: an international registry study (2022) (0)
Wide variation in pre-procedural blood product transfusion practices in cirrhosis: a national multidisciplinary survey (2023) (0)
Title Silencing of Jagged 1 inhibits cell growth and invasion incolorectal cancer (2014) (0)
MAFLD: How is it different from NAFLD? (2022) (0)
Low alanine aminotransferase and higher cardiovascular events in type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (2017) (0)
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD (2022) (0)
Nonalcoholic Fatty Liver Disease in Latin America and Australia. (2023) (0)
1301 ENDOTOXIN CAUSES HIGH MORTALITY AND REDUCED HEPATIC SYNTHESIS OF ACUTE PHASE PROTEINS IN RATS WITH EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE (2013) (0)
Non-alcoholic fatty liver disease. (2005) (0)
Serum TNF-α and sarcopenia in liver cirrhosis Prevalence trends of NAFLD among young Korean men Surgery vs. RFA in single small HCC Galectin-3 and (2022) (0)
Exercise and visceral fat loss: is waist circumference a useful predictor? (2015) (0)
The Endocrinology of Liver Disease (2021) (0)
A new role for IKK‐α in hepatitis C virus‐induced lipogenesis (2014) (0)
OC-10Liver-related and extrahepatic events occurrence in patients with nonalcoholic fatty liver disease: a competing risk analysis (2021) (0)
Characteristics of the Randomized Cohorts and SVR Rates of Heterozygous Genotype rs 12979860 CT With Additional Genotyping of rs 8099917 (2013) (0)
Su1043 Nonalcoholic Fatty Liver Disease and Cardiovascular Mortality in Older Individuals: A Prospective Cohort Study (2015) (0)
[Non-alcoholic fatty liver]. (2010) (0)
The Importance and Impact of Recognizing MAFLD in Patients With Chronic Hepatitis C (2021) (0)
Differential expression of CYP genes in patients with severe liver disease (1993) (0)
Non-invasive liver fibrosis markers, FIB-4, PRO-C3 and ADAPT, are significantly elevated in biopsy confirmed NAFLD patients at high risk of developing coronary heart disease and cardiovascular disease and are promising clinical decision making tools (2020) (0)
Improved survival following Hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia (2019) (0)
813 HEPATITIS C VIRUS-SPECIFIC CELLULAR IMMUNITY DOES NOT PROTECT AGAINST FUTURE HCV INFECTION IN ANTI-HCV NEGATIVE INJECTING DRUG USERS (2011) (0)
Su1406 Intrafamilial Transmission of Chronic HBV Infection: Results of a Large Population-Based Cohort Study (2015) (0)
Editorial: metformin for portal hypertension—old dog, new tricks? Authors' reply (2021) (0)
Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study (2020) (0)
P660 THE EFFECT OH HEPATITIS B VIRUS INFECTION ON STEATOSIS IN HEPATITIS C VIRUS COINFECTED PATIENTS: THE BOSTIC STUDY (2014) (0)
Risk factors for short-term post discharge clinical outcomes in patients hospitalized with decompensated chronic liver disease: interim results from Global CLEARED study (2022) (0)
Erratum to ‘Ltb4r1 inhibitor: A pivotal insulin sensitizer?’ [Trends in Endocrinology and Metabolism, May 2015, Vol. 26, No. 5, 221-222] (2016) (0)
P1018 MARKERS OF COLLAGEN REMODELING DETECT CLINICALLY SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS C PATIENTS (2014) (0)
P0974 : Effects of resveratrol on experimental non-alcoholic steatohepatitis (2015) (0)
Cancer Biology and Signal Transduction Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6 / STAT 3 Signaling (2014) (0)
Interferon lambda drives a pro-inflammatory phenotype in macrophages (2016) (0)
STAT4 variants increase liver fibrosis risk in chronic hepatitis B through impaired STAT4- dependent NK cell IFN-γ production (0)
Reply: (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jacob George?

Jacob George is affiliated with the following schools:

University of Sydney
University of Melbourne
Monash University